Viropro subsidiary BPD expands lab services

By Alexandria Pesic

- Last updated on GMT

Related tags Subsidiary Biotechnology

Biologics Process Development, a wholly-owned subsidiary of Californian contract research organisation (CRO), Viropro, has announced it is to double the size of its bioprocess and scale-up laboratory.

The company, which specialises in providing contract laboratory services for the biotech and biopharma industries, claims the expansion will allow it to better serve the needs of existing clients who demand larger processing volumes, whilst potentially attracting new business.

In addition, the company has announced various changes at boardroom level, including the appointment of former BioProcess Technology Consultants (BTC) founder, Howard Levine and former vice president of EU and US pharmaceutical development at Japanese firm, Santen, Pete Fernandes.

Fernandes was previously involved in both the technical and strategic management of early and late-stage drug development of recombinant-derived biologicals and small molecules.

Meanwhile, prior to founding BTC, Levine held positions in process development at both Genentech and Amgen.

Share deal

Virorpro acquired BPD in 2010 after brokering a deal which saw BPD’s Indian owners, Intas, receive 90 million shares in return. The companies planned to integrate their activities in the area of biotech contract research and manufacturing services (CRAM).

Speaking at the time of the deal, Virorpro president Serge Beausoleil, said: “Both Viropro and Intas share a common goal of creating a global biotech CRAMS footprint that utilises the strengths of each of its constituent companies and partners towards providing a seamless clone-to-clinic offering.”

Business plan

News of BPD’s lab expansion comes soon after parent company Viropro released an update of its long term business plan, claiming its mission is to “become the premier provider of outsourced research, development and manufacturingservices for the biopharmaceutical industry.”

The company said the market for biopharmaceutical drugs stood at an estimated $75bn (€53bn), with the rapidly developing Japanese and European markets set to exceed $2bn (€1.4bn) by 2015, driven primarily by an aging population.

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us